

More Insights In Sight

Tumor genomic profiling with
Agilent SureSelect Cancer assays



SureSelect Cancer assays

Unlock the full potential of comprehensive genomic profiling (CGP) to advance precision oncology with the Agilent SureSelect Cancer assays, a portfolio of targeted resequencing assays based on next-generation sequencing (NGS) technology. The SureSelect Cancer portfolio includes catalog and custom panels for mutation detection in cancer-associated genes from solid tumors. You'll have access to the most clinically relevant and up-to-date biomarkers with gene content curated globally in consultation with leading cancer researchers, and drawing from established clinical guidelines, ongoing clinical trials, and somatic cancer databases.

The SureSelect Cancer assays enable you to detect key classes of somatic variants and assess immuno-oncology biomarkers and homologous recombination deficiency. Have confidence in high-performance results optimized with error-correcting molecular barcodes, convenient enzymatic fragmentation and minimum sample input. The workflow solution is configurable to meet the needs of your lab with options to incorporate sample and NGS library QC, automation, and data analysis solutions.

Gain insight into cancer types



Lung



Breast



Prostate



Colorectal



Gastric



Bladder



Kidney



Melanoma



Pancreatic

Detect key classes of mutations

Somatic variants



SNVs



TLs



Indels



CNVs

Immuno-oncology biomarkers



TMB



MSI

Homologous recombination deficiency



HRD

RNA gene fusions



Gene fusions

Comprehensive pan-cancer panel

DNA assay
679 genes

RNA assay
80 genes

SureSelect Cancer CGP assay

Perform CGP with a pan-cancer catalog panel. You can sequence DNA and RNA in parallel to detect key classes of somatic alterations.

Tumor-specific panels

DNA assay
~50 genes

SureSelect Cancer Tumor-Specific assays

Perform tumor genomic profiling at lower cost with focused panels, based on subsets of gene content from the SureSelect Cancer CGP panel.

Customized panels

DNA assay
750* genes

SureSelect Cancer Custom panels

Incorporate new and emerging biomarkers by customizing your gene content with SureDesign software. Based on your laboratory requirements, leverage gene content from SureSelect Cancer catalog DNA panels.

Table 1. Somatic alterations detected by SureSelect Cancer assays.




Variant class		SureSelect Cancer CGP assay	SureSelect Cancer Tumor-Specific assays	SureSelect Cancer Custom assays
Somatic variants (DNA)	Single nucleotide variants (SNVs)	✓	✓	✓
	Insertions / Deletions (Indels)	✓	✓	✓
	Copy number variants (CNV)	✓	✓	✓
	Translocations (TLs)	✓	✓	✓
Somatic variants (RNA)	Gene fusions	✓	**	**
Immuno-oncology biomarkers (DNA)	Tumor mutational burden (TMB)	✓		✓
	Microsatellite instability (MSI)	✓		✓
Homologous recombination deficiency (DNA)	Homologous recombination deficiency (HRD)	✓		✓

* The number shown here is for illustrative purposes only. The number of genes in a SureSelect Cancer Custom panel depends on the user design requirements, with panel sizes ranging from 1 Kb to 24 Mb.

** Assays can be paired with the SureSelect Cancer CGP RNA assay for gene fusion detection.

Customize your panels with Agilent SureDesign

Create your SureSelect Cancer Custom panels for comprehensive genomic profiling of tumor samples to fit your lab's specific requirements, including the assessment of new and emerging biomarkers and immuno-oncology biomarkers TMB and MSI.



User friendly software

Easy panel customization with SureDesign, a next-generation web design portal for probe design powered by machine learning

Leverage curated content

Draw on globally curated genes from SureSelect Cancer catalog DNA panels to add or subtract genes for your custom panel design

Go from design to quote

Rapid design for your custom panels with convenient quoting in SureDesign software




Reliable target enrichment chemistry

SureSelect Cancer assays are powered by proven, high-performance library prep and target enrichment chemistry (SureSelect XT HS2), which delivers optimal target coverage and high-complexity libraries for detection of low-frequency variant alleles and robust coverage of difficult to sequence, GC-rich genes, such as CEBPA.




Fast hybridization

Only 90 minutes for target capture, enabling a faster workflow resulting in sequencing-ready libraries in nine hours.



Error correcting molecular barcodes

Unique molecular identifiers (UMIs) detect low-frequency variant alleles with sensitivity and accuracy and unique dual index (UDIs) correct for index hopping.



Enzymatic fragmentation


Optional enzymatic fragmentation eliminates the need for physical shearing equipment for optimal convenience, and may improve library complexity and read coverage.



Low sample input

Start with as little as 10 ng (recommended 50 ng) to as much as 200 ng nucleic acid from formalin-fixed, paraffin-embedded (FFPE) or fresh-frozen tissues, enabling more samples to be profiled.


A flexible NGS workflow solution



Achieve high-complexity NGS libraries with a flexible and efficient workflow. Opt for automated library preparation and target enrichment to go from nucleic acid sample QC to sequencing results in less than four days. Match your sample throughput to a range of compatible sequencers from Illumina, Element Biosciences, Pacific Biosciences, and MGI. Assess clinically relevant variants with the data analysis and annotation solution best suited to your lab.



3.5 days to sequencing results



Automation options



Data analysis options

Sample & library QC



High-quality results depend on high-quality sample input. **Agilent TapeStation systems** are automated electrophoresis solutions for quality control of a wide range of DNA and RNA samples. Proven ScreenTape technology guarantees superior ease-of-use, and lets you analyze size, quantity, and integrity of your sample.

Automation for library prep and target enrichment

Prepare high-quality, sequencing-ready libraries with more consistency and lab efficiency using automation solutions for library preparation and target enrichment. Choose between two automation platforms from Agilent, both of which support enzymatic fragmentation of DNA, reverse transcription for RNA, and bead cleanup. These automation platforms offer a reagent rental program for SureSelect reagents to offset capital equipment expense.



The Magnis NGS Prep system is an easy-to-use, fully automated benchtop platform that requires minimal staff and NGS expertise to run. The pre-aliquoted reagents and preset protocols enable set up with only 15 min hands-on time for walkaway convenience. Onboard quality assurance capabilities include a UV light for decontamination between runs, and automated barcode scanning for correct consumables placement. The Magnis NGS Prep system can prepare up to 8 libraries per run, and up to two runs per day (2 shifts).



The Bravo NGS Workstation is a liquid handling platform for increased throughput, allowing the user to scale and prepare up to 96 libraries simultaneously, while maintaining reproducibility and quality. The open automation platform provides user flexibility in applications to adjust and optimize other assays in development.

Data analysis solutions

Data analysis options for the SureSelect Cancer assays include software solutions that are optimized for Agilent NGS chemistries with Agilent Alissa Reporter and compatible with customer's inhouse or third-party software, such as SOPHiA GENETICS.

Table 2. Gene content (DNA) in the SureSelect Cancer CGP assay, which are also available for use in designing SureSelect Cancer Custom panels.

SNVs/Indels											CNV	Translocations	
ABL1	BRAF	CRBN	EPHB2	FLI1	HNF1A	KRAS	MYH9	PIAS3	RAB35	SIN3A	TFE3	ALK	ALK: [18, 19]
ABL2	BRCA1	CREBBP	EPHB4	FLT1	HNRNPK	LAMP1	MYOD1	PIAS4	RAC1	SLC34A2	TFEB	AR	BRAF: [8, 9, 10]
ABR	BRCA2	CRKL	ERBB2	FLT3	HOXB13	LATS1	NAB2	PIK3C2B	RAD21	SLIT2	TFRC	BARD1	CIC: [18, 19]
ACVR1	BRD4	CRLF2	ERBB3	FLT4	HOXC6	LATS2	NBN	PIK3C2G	RAD50	SLX4	TGFBR1	BRAF	EGFR: [24, 25, 26]
ACVR1B	BRIP1	CSAD	ERBB4	FOXA1	HRAS	LMO1	NCOA2	PIK3C3	RAD51	SMAD2	TGFBR2	BRCA1	FGFR1: [3, 4, 5, 6, 7, 8, 9]
ACVR2A	BTG1	CSF1R	ERCC1	FOXA2	HSD3B1	LRP1B	NCOA3	PIK3CA	RAD51B	SMAD3	TIPARP	BRCA2	FGFR2: [17]
ADGRA2	BTG2	CSF3R	ERCC2	FOXL2	HSP90AA1	LTK	NCOR1	PIK3CB	RAD51C	SMAD4	TLR4	BRIP1	FGFR3: [17, 18]
AJUBA	BTK	CSNK1A1	ERCC3	FOXO1	ICOSLG	LYN	NCOR2	PIK3CD	RAD51D	SMARCA4	TMEM127	CCND1	NTRK1: [8, 9, 10, 11]
AKAP9	C11ORF30	CTCF	ERCC4	FOXP1	ID3	LZTR1	NEGR1	PIK3CG	RAD52	SMARCB1	TMPRSS2	CCND2	RAF1: [7, 8, 9]
AKT1	CALR	CTLA4	ERCC5	FRS2	IDH1	MAF	NF1	PIK3R1	RAD54L	SMARCD1	TNFAIP3	CCNE1	RET: [7, 10, 11]
AKT2	CARD11	CTNNA1	ERG	FUBP1	IDH2	MAGEC3	NF2	PIK3R2	RAF1	SMARCE1	TNFRSF14	CD274	ROS1: [31, 33, 34, 35]
AKT3	CASP8	CTNNA1	ERRFI1	FYN	IDO1	MAGI2	NFE2L2	PIK3R3	RANBP2	SMC1A	TOP1	CDK4	TMPRSS2: [1, 2, 3, 4]
ALK	CASR	CTRC	ESR1	GABRA6	IDO2	MALT1	NFKB2	PIM1	RARA	SMC3	TOP2A	CDK6	
ALOX12B	CBFB	CUL3	ESR2	GATA1	IFNGR1	MAML2	NFKBIA	PIM2	RASA1	SMG1	TP53	CDKN2A	
ALOX15B	CBL	CUL4A	ETS1	GATA2	IFNGR2	MAP2K1	NKX2-1	PIM3	RB1	SMO	TP53BP1	EGFR	
AMER1	CBLB	CUL4B	ETV1	GATA3	IGF1	MAP2K2	NKX3-1	PLCG1	RBM10	SNCAIP	TP63	ERBB2	
ANKRD11	CCND1	CUX1	ETV4	GATA4	IGF1R	MAP2K4	NLRC5	PLCG2	RECQL4	SOCS1	TP73	FGFR1	
ANKRD26	CCND2	CXCR4	ETV5	GATA6	IGF2	MAP3K1	NOTCH1	PLK2	REL	SOS1	TRAF2	FGFR2	
APC	CCND3	CYLD	ETV6	GEN1	IKBKE	MAP3K13	NOTCH2	PMAIP1	REST	SOX10	TRAF3	FGFR3	
APLN	CCNE1	CYP17A1	EWSR1	GID4	IKZF1	MAP3K14	NOTCH3	PML	RET	SOX17	TRAF7	KEAP1	
AR	CD22	DAXX	EZH2	GLI1	IKZF3	MAP3K4	NOTCH4	PMS1	RFWD2	SOX2	TSC1	KRAS	
ARAF	CD274	DCUN1D1	EZR	GNA11	IL10	MAP3K7	NPM1	PMS2	RFX5	SOX9	TSC2	MDM2	
ARFRP1	CD276	DDR1	FAM175A	GNA13	IL6R	MAPK1	NR3C1	PNRC1	RFXAP	SPEN	TSHR	MET	
ARHGAP26	CD38	DDR2	FAM46C	GNAI2	IL6ST	MAPK3	NRAS	POLD1	RHEB	SPINK1	TYR	MYC	
ARHGAP35	CD44	DDX3X	FANCA	GNAQ	IL7R	MAX	NRG1	POLE	RHOA	SPOP	TYRO3	MYCN	
ARID1A	CD58	DDX41	FANCC	GNAS	ING1	MC1R	NSD1	POLQ	RICTOR	SPTA1	UZAF1	PALB2	
ARID1B	CD70	DDX5	FANCD2	GPC3	INHBA	MCL1	NT5C2	POT1	RIT1	SRC	UGT1A1	PIK3CA	
ARID2	CD74	DEFB134	FANCE	GPS2	INHBA	MDC1	NTHL1	PPARG	RNASEL	SRSF2	UVRAG	PTEN	
ARID5B	CD79A	DHX15	FANCF	GRB2	INPP4A	MDM2	NTRK1	PPM1D	RNF43	STAG1	VEGFA	RAD51C	
ASXL1	CD79B	DHX9	FANCG	GREM1	INPP4B	MDM4	NTRK2	PPP2R1A	ROS1	STAG2	VHL	RAD51D	
ASXL2	CDC73	DICER1	FANCI	GRIN2A	INSR	MECOM	NTRK3	PPP2R2A	RPL22	STAT1	VTCN1	STK11	
ATM	CDH1	DIS3	FANCL	GRM3	IRF1	MED12	NUP93	PPP4R2	RPL5	STAT3	WHSC1	TP53	
ATR	CDK12	DIS3L2	FANCM	GSK3B	IRF2	MEF2B	NUTM1	PPP6C	RPS6KA4	STAT4	WHSC1L1		
ATRX	CDK2	DLX1	FAS	H3F3A	IRF4	MEN1	P2RY8	PRAME	RPS6KB1	STAT5A	WISP3		
AURKA	CDK4	DNAJB1	FAT1	H3F3B	IRS1	MERTK	PAK1	PRC1	RPS6KB2	STAT5B	WRN		
AURKB	CDK6	DNMT1	FBXO11	H3F3C	IRS2	MET	PAK3	PRDM1	RPTOR	STAT6	WT1		
AURKC	CDK7	DNMT3A	FBXW7	HDAC1	JAK1	MGA	PAK7	PREX2	RRM1	STK11	XBP1		
AXIN1	CDK8	DNMT3B	FGF1	HGF	JAK2	MGMT	PALB2	PRKAR1A	RSPO2	STK40	XIAP		
AXIN2	CDKN1A	DOT1L	FGF10	HIF1A	JAK3	MITF	PARK2	PRKCI	RUNX1	SUFU	XPO1		
AXL	CDKN1B	DPYD	FGF12	HIST1H1C	JUN	MKNK1	PARP1	PRKDC	RUNX1T1	SUZ12	XRCC2		
B2M	CDKN1C	E2F3	FGF14	HIST1H2BD	KAT6A	MLH1	PARP2	PRSS1	RXRA	SYK	YAP1		
BAP1	CDKN2A	EED	FGF19	HIST1H3A	KDM5A	MLL3	PARP3	PRSS8	RYBP	TAF1	YES1		
BARD1	CDKN2B	EGFL7	FGF2	HIST1H3B	KDM5C	MPL	PAX3	PSIP1	SDC4	TAF3	ZBTB2		
BBC3	CDKN2C	EGFR	FGF23	HIST1H3C	KDM6A	MRE11A	PAX5	PSMA1	SDHA	TAP1	ZBTB7A		
BCL10	CEBPA	EIF1AX	FGF3	HIST1H3D	KDR	MSH2	PAX7	PSMB5	SDHAF2	TAP2	ZFHX3		
BCL2	CENPA	EIF4A2	FGF4	HIST1H3E	KEAP1	MSH3	PAX8	PSMD1	SDHB	TAPBP	ZFP36L1		
BCL2L1	CFTR	EIF4E	FGF5	HIST1H3F	KEL	MSH6	PBRM1	PSMG2	SDHC	TBL1XR1	ZMYM2		
BCL2L11	CHD2	ELAC2	FGF6	HIST1H3G	KIAA1549	MST1	PCBP1	PTCH1	SDHD	TBX3	ZMYM3		
BCL2L2	CHD4	ELF3	FGF7	HIST1H3H	KIF5B	MST1R	PDCD1	PTEN	SERPIN3	TCEB1	ZNF217		
BCL6	CHD8	EML4	FGF8	HIST1H3I	KIT	MTAP	PDCD1LG2	PTK2	SERPIN4	TCF12	ZNF703		
BCOR	CHEK1	EP300	FGF9	HIST1H3J	KLF2	MTOR	PDGFRA	PTPN11	SETBP1	TCF3	ZNF750		
BCORL1	CHEK2	EPCAM	FGFR1	HIST2H3C	KLF4	MUTYH	PDGFRB	PTPRD	SETD2	TCF7L2	ZRSR2		
BCR	CIC	EPHA2	FGFR2	HIST2H3D	KLHL6	MYB	PDK1	PTPRO	SF3B1	TEK			
BIRC2	CIITA	EPHA3	FGFR3	HIST3H3	KMT2A	MYC	PDPK1	PTPRS	SGK1	TERC			
BIRC3	CKS1B	EPHA5	FGFR4	HLA-A	KMT2B	MYCL	PGR	PTPRT	SH2B3	TERT			
BLM	COL17A1	EPHA7	FH	HLA-B	KMT2C	MYCN	PHF6	QKI	SH2D1A	TET1			
BMPR1A	CPA1	EPHB1	FLCN	HLA-C	KMT2D	MYD88	PHOX2B	QSER1	SHQ1	TET2			

Table 3. Gene content (RNA) in the SureSelect Cancer CGP assay.

Fusion Genes									
<i>ABL1</i>	<i>BRCA1</i>	<i>EML4</i>	<i>ETV6</i>	<i>FLT1</i>	<i>MAML2</i>	<i>MYB</i>	<i>NTRK3</i>	<i>PKN1</i>	<i>RPS6KB1</i>
<i>AKT3</i>	<i>BRCA2</i>	<i>ERBB2</i>	<i>EWSR1</i>	<i>FLT3</i>	<i>MAST1</i>	<i>MYC</i>	<i>NUMBL</i>	<i>PPARG</i>	<i>RSP02</i>
<i>ALK</i>	<i>BRD3</i>	<i>ERG</i>	<i>FGFR1</i>	<i>INSR</i>	<i>MAST2</i>	<i>NOTCH1</i>	<i>NUTM1</i>	<i>PRKCA</i>	<i>RSP03</i>
<i>AR</i>	<i>BRD4</i>	<i>ESR1</i>	<i>FGFR2</i>	<i>JAK2</i>	<i>MET</i>	<i>NOTCH2</i>	<i>PAX3</i>	<i>PRKCB</i>	<i>TERT</i>
<i>ARHGAP26</i>	<i>CDK4</i>	<i>ETS1</i>	<i>FGFR3</i>	<i>KDR</i>	<i>MLLT3</i>	<i>NOTCH3</i>	<i>PAX7</i>	<i>RAF1</i>	<i>TFE3</i>
<i>AXL</i>	<i>CIC</i>	<i>ETV1</i>	<i>FGFR4</i>	<i>KIF5B</i>	<i>MSH2</i>	<i>NRG1</i>	<i>PDGFRA</i>	<i>RELA</i>	<i>TFEB</i>
<i>BCL2</i>	<i>CSF1R</i>	<i>ETV4</i>	<i>FGR</i>	<i>KIT</i>	<i>MSMB</i>	<i>NTRK1</i>	<i>PDGFRB</i>	<i>RET</i>	<i>THADA</i>
<i>BRAF</i>	<i>EGFR</i>	<i>ETV5</i>	<i>FLI1</i>	<i>KMT2A</i>	<i>MUSK</i>	<i>NTRK2</i>	<i>PIK3CA</i>	<i>ROS1</i>	<i>TMPRSS2</i>

Table 4. Gene content (DNA) in the SureSelect Cancer Tumor-Specific assays, which are also available for use in designing SureSelect Cancer Custom panels.

SureSelect Cancer Lung assay

SNVs/Indels									CNV		Translocations
AKT1	CCND1	CDK6	ERBB3	HRAS	KRAS	MSH6	NTRK3	RAF1	BRAF	EGFR	ALK:[18,19]
ALK	CCND2	CDKN2A	ERCC2	IDH1	MAP2K1	MTOR	PDGFRA	RET	CCND1	ERBB2	FGFR2:[17]
APC	CCNE1	CTNNB1	FGFR1	IDH2	MAP2K2	NF1	PIK3CA	ROS1	CCND2	FGFR1	FGFR3:[17,18]
ARAF	CD274	DDR2	FGFR2	KDM6A	MET	NRAS	PMS2	STK11	CD274	MET	NTRK1:[8,9,10,11]
ARID1A	CDK12	EGFR	FGFR3	KEAP1	MLH1	NTRK1	PTCH1	TP53	CDK6	PIK3CA	RET:[7,10,11]
BRAF	CDK4	ERBB2	FGFR4	KIT	MSH2	NTRK2	PTEN		CDKN2A	PTEN	ROS1:[31,33,34,35]

SureSelect Cancer Colon assay

SNVs/Indels									CNV		Translocations
APC	BRAF	CTNNB1	FBXW7	MLH1	MUTYH	PIK3CA	PTEN	STK11	CDKN2A	PIK3CA	BRAF:[8,9,10]
ARID1A	CDH1	EPCAM	GNAS	MSH2	MYC	PMS2	RNF43	TCF7L2	ERBB2	PTEN	
AXIN2	CDKN2A	ERBB2	GREM1	MSH3	NRAS	POLD1	SMAD4	TP53	KRAS		
BMPR1A	CHEK2	ERBB3	KRAS	MSH6	NTHL1	POLE	SOX9		MYC		

SureSelect Cancer Pancreas assay

SNVs/Indels									CNV		Translocations
ALK	BRCA1	CPA1	FBXW7	MDM2	NF1	POLD1	SMAD4	TSC2	BRCA1		ALK:[18,19]
APC	BRCA2	CTNNB1	FGFR2	MEN1	NRAS	POLE	SOX9	VHL	BRCA2		FGFR2:[17]
ARID1A	CASR	CTRC	GNAS	MET	NRG1	PRSS1	SPINK1		ERBB2		NTRK1:[8,9,10,11]
ATM	CDH1	EPCAM	IDH1	MLH1	NTRK1	PTEN	STK11		KRAS		RET:[7,10,11]
BAP1	CDKN2A	ERBB2	IDH2	MSH2	PALB2	RET	TCF7L2		MDM2		ROS1:[31,33,34,35]
BMPR1A	CFTR	ERBB3	KRAS	MSH6	PIK3CA	RNF43	TP53		MET		
BRAF	CHEK2	ESR1	MAP2K1	MYC	PMS2	ROS1	TSC1		MYC		

SureSelect Cancer Kidney assay

SNVs/Indels									CNV	
ATM	DICER1	FLCN	MLH1	NF2	PTEN	SDHC	SMARCB1	TSC2	MET	
BAP1	DIS3L2	GPC3	MSH2	PBRM1	REST	SDHD	TFEB	VHL	PIK3CA	
CDC73	EPCAM	KDM5C	MSH6	PIK3CA	SDHA	SETD2	TP53	WT1	PTEN	
CDKN1C	FH	MET	MTOR	PMS2	SDHB	SMARCA4	TSC1			

SureSelect Cancer Bladder assay

SNVs/Indels							CNV		Translocations
AKT1	CCND1	CTNNB1	ERCC2	KDM6A	PPARG	TSC1	CCND1	KRAS	BRAF:[8,9,10]
ARID1A	CCNE1	E2F3	FGFR2	KRAS	PTEN		CCNE1	MDM2	FGFR2:[17]
ATM	CDKN1A	ERBB2	FGFR3	MDM2	RB1		CDKN2A	PIK3CA	FGFR3:[17,18]
BRAF	CDKN2A	ERBB3	HRAS	PIK3CA	TP53		ERBB2	PTEN	

Table 5. Additional curated tumor-specific gene content (DNA) that are available for use in designing SureSelect Cancer Custom panels.

SureSelect Cancer Breast panel

SNVs/Indels									CNV		Translocations
AKT1	BRCA2	CHEK2	FANCA	KRAS	MSH2	NRG1	POLE	RAD51D	BARD1	MYC	BRAF:[8,9,10]
ARID1A	BRIP1	CTNNB1	FANCD2	MAGEC3	MSH6	NTRK3	PPP2R1A	RAD54L	BRCA1	PALB2	FGFR2:[17]
ATM	CCNE1	EPCAM	FBXW7	MAP2K1	MTOR	PALB2	PPP2R2A	RB1	BRCA2	PIK3CA	
BARD1	CDH1	ERBB2	FGFR1	MET	MYC	PIK3CA	PTEN	STK11	BRIP1	PTEN	
BRAF	CDK12	ERBB3	FGFR2	MLH1	NBN	PIK3R1	RAD51B	TP53	ERBB2	RAD51C	
BRCA1	CDKN2A	ESR1	FGFR3	MRE11	NF1	PMS2	RAD51C		KRAS	RAD51D	

SureSelect Cancer Prostate panel

SNVs/Indels									CNV		Translocations
AKT1	BRCA2	EPCAM	FOXA1	KMT2D	MUTYH	PIK3CA	RAD51C	STK11	AR		BRAF:[8,9,10]
APC	BRIP1	ERG	GATA2	KRAS	MYC	PIK3R1	RAD51D	TMPRSS2	BRCA1		TMPRSS2: [1, 2, 3, 4]
AR	CDH1	ETV1	HOXB13	MAGEC3	NBN	PMS2	RAD54L	TP53	BRCA2		
ATM	CDK12	ETV4	HRAS	MED12	NCOA2	PPP2R2A	RB1		KRAS		
BARD1	CHEK1	ETV5	IDH1	MLH1	NCOR2	PTEN	SPINK1		MYC		
BRAF	CHEK2	FANCA	KDM6A	MSH2	PALB2	RAD50	SPOP		PIK3CA		
BRCA1	CTNNB1	FANCL	KMT2C	MSH6	PARP1	RAD51B	SPTA1		PTEN		

SureSelect Cancer Melanoma panel

SNVs/Indels									CNV		Translocations
AKT3	BRCA1	CDKN2A	GNA11	IDH1	MC1R	NRAS	PTEN	TP53	BRCA1	KRAS	BRAF:[8,9,10]
ARID2	BRCA2	CTNNB1	GNAQ	KIT	MDM2	PIK3CA	RAC1	TYR	BRCA2	MDM2	
BAP1	CCND1	ERBB4	GRIN2A	KRAS	MITF	POT1	RB1		CCND1	PIK3CA	
BRAF	CDK4	EZH2	HRAS	MAP2K1	NF1	PPP6C	TERT		CDK4	PTEN	

SureSelect Cancer Gastric panel

SNVs/Indels								CNV	
APC	CDH1	EPCAM	KIT	MSH2	PIK3CA	SDHA	STK11	CCND1	KRAS
ARID1A	CDKN2A	ERBB2	KMT2C	MSH6	PMS2	SDHB	TP53	CCNE1	MYC
BMPR1A	CTNNA1	ERBB3	KMT2D	MYC	PTEN	SDHC		CDKN2A	PIK3CA
CCND1	CTNNB1	FBXW7	KRAS	NF1	RHOA	SDHD		EGFR	PTEN
CCNE1	EGFR	GNAS	MLH1	PDGFRA	RNF43	SMAD4		ERBB2	

Learn more:

www.agilent.com

Buy online:

www.agilent.com/store

U.S. and Canada

1-800-227-9770

agilent_inquiries@agilent.com

Europe

info_agilent@agilent.com

Asia Pacific

inquiry_lsca@agilent.com



Altium International Sp. z o.o.

ul. Puławska 303, 02-785 Warszawa

telefon +48 22 549 14 00

bio.pl@altium.net

www.perlan.com.pl

www.altium.net

**All products mentioned in this brochure are "For Research Use Only.
Not for use in diagnostic procedures".**

PR7001-2287

This information is subject to change without notice.

© Agilent Technologies, Inc. 2023-2024
Published in the USA, April 1, 2024
5994-5801EN

